Mesoblast Limited (NASDAQ:MESO) Given Consensus Rating of “Hold” by Brokerages

Mesoblast Limited (NASDAQ:MESO) has received an average recommendation of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $13.67.

MESO has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a research report on Thursday, June 20th. StockNews.com lowered Mesoblast from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Mesoblast stock. Chase Investment Counsel Corp purchased a new position in shares of Mesoblast Limited (NASDAQ:MESO) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 59,600 shares of the company’s stock, valued at approximately $298,000. Chase Investment Counsel Corp owned about 0.05% of Mesoblast at the end of the most recent quarter. 1.43% of the stock is currently owned by institutional investors and hedge funds.

Mesoblast Stock Performance

MESO stock opened at $6.81 on Wednesday. The firm has a 50-day simple moving average of $7.23 and a two-hundred day simple moving average of $4.30. Mesoblast has a one year low of $1.61 and a one year high of $10.24. The firm has a market cap of $777.55 million, a price-to-earnings ratio of -6.08 and a beta of 3.46.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.